Quantitative Receptor-Based Imaging of Tumor Proliferation with the Sigma-2 Ligand [18F]ISO-1

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Shoghi, Kooresh I ^a   Xu, Jinbin ^a   Su, Yi ^a   He, June ^a   Rowland, Douglas ^b   Yan, Ying ^a   Garbow, Joel R ^a   Tu, Zhude ^a   Jones, Lynne A ^a   Higashikubo, Ryuji ^a   Wheeler, Kenneth T ^c   Lubet, Ronald A ^d   Mach, Robert H ^a   You, Ming ^a,e  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 FLUOROETHOXY) N [4 (3,4 DIHYDRO 6,7 DIMETHOXYISOQUINOLIN 2(1H) YL)BUTYL] 5 METHYLBENZAMIDE F 18; BEXAROTENE; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VOROZOLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG RESPONSE; DRUG UPTAKE; FEMALE; FLOW CYTOMETRY; IMAGE ANALYSIS; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; RADIOACTIVITY; RAT; RECEPTOR DENSITY; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME;

ALKYLATING AGENTS; ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; BENZAMIDES; BLOTTING, WESTERN; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIGANDS; MAMMARY NEOPLASMS, ANIMAL; METHYLNITROSOUREA; MICE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RECEPTORS, SIGMA; TETRAHYDRONAPHTHALENES; TRIAZOLES; TUMOR CELLS, CULTURED;

EID: 84884477756     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074188     Document Type: Article

References (39)

1. Eubank WB, Mankoff DA, (2005) Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 35: 84-99.
2. Kumar R, Alavi A (2004) Fluorodeoxyglucose-PET in the management of breast cancer. Radiol Clin North Am 42: 1113-1122, ix.
3. Avril N, Menzel M, Dose J, Schelling M, Weber W, et al. (2001) Glucose metabolism of breast cancer assessed by 18F-FDG PET: Histologic and immunohistochemical tissue analysis. J Nucl Med 42: 9-16.
4. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, et al. (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4: 1334-1336.
5. Mach RH, Zeng C, Hawkins WG (2013) The sigma Receptor: A Novel Protein for the Imaging and Treatment of Cancer. J Med Chem.
6. Loddo M, Kingsbury SR, Rashid M, Proctor I, Holt C, et al. (2009) Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br J Cancer 100: 959-970.
7. Fornace AJ, Fuks Z, Weichselbaum RR, Milas L (2001) Radiation Therapy. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA, editors. The Molecular Basis of Cancer. Philadelphia, PA: W. B. Saunders Co. 423-466.
8. Collins I, Garrett MD, (2005) Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol 5: 366-373.
9. Strebhardt K, Ullrich A, (2006) Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6: 321-330.
10. Scholzen T, Gerdes J, (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322.
11. Bem WT, Thomas GE, Mamone JY, Homan SM, Levy BK, et al. (1991) Overexpression of sigma receptors in nonneural human tumors. Cancer Res 51: 6558-6562.
12. Mach RH, Smith CR, al-Nabulsi I, Whirrett BR, Childers SR, et al. (1997) Sigma 2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res 57: 156-161.
13. Vilner BJ, John CS, Bowen WD, (1995) Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 55: 408-413.
14. Al-Nabulsi I, Mach RH, Wang LM, Wallen CA, Keng PC, et al. (1999) Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells. Br J Cancer 81: 925-933.
15. Wheeler KT, Wang LM, Wallen CA, Childers SR, Cline JM, et al. (2000) Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer 82: 1223-1232.
16. Tu Z, Xu J, Jones LA, Li S, Dumstorff C, et al. (2007) Fluorine-18-labeled benzamide analogues for imaging the sigma2 receptor status of solid tumors with positron emission tomography. J Med Chem 50: 3194-3204.
17. Tu Z, Dence CS, Ponde DE, Jones L, Wheeler KT, et al. (2005) Carbon-11 labeled sigma2 receptor ligands for imaging breast cancer. Nucl Med Biol 32: 423-430.
18. Kashiwagi H, McDunn JE, Simon PO Jr, Goedegebuure PS, Xu J, et al. (2007) Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol Cancer 6: 48.
19. Dehdashti F, Laforest R, Gao F, Shoghi KI, Aft RL, et al. (2013) Assessment of cellular proliferation in tumors by PET using 18F-ISO-1. J Nucl Med 54: 350-357.
20. Gullino PM, Pettigrew HM, Grantham FH, (1975) N-nitrosomethylurea as mammary gland carcinogen in rats. J Natl Cancer Inst 54: 401-414.
21. Huggins C, (1965) Two principles in endocrine therapy of cancers: hormone deprival and hormone interference. Cancer Res 25: 1163-1167.
22. Lubet RA, Christov K, Nunez NP, Hursting SD, Steele VE, et al. (2005) Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis. Carcinogenesis 26: 441-448.
23. Xu J, Tu Z, Jones LA, Vangveravong S, Wheeler KT, et al. (2005) [3H]N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-methoxy-5-methylbenzamide: A novel sigma-2 receptor probe. Eur J Pharmacol 525: 8-17.
24. Scatchard G, (1949) The attractions of proteins for small molecules and ions. Ann NY Acad Sci 51: 662-672.
25. Laforest R, Longford D, Siegel S, Newport DF, Yap J, (2007) Performance evaluation of the microPET (R)- FOCUS-F120. Ieee Transactions on Nuclear Science 54: 42-49.
26. Tai YC, Ruangma A, Rowland D, Siegel S, Newport DF, et al. (2005) Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med 46: 455-463.
27. Wallen CA, Higashikubo R, Dethlefsen LA, (1984) Murine mammary tumour cells in vitro. II. Recruitment of quiescent cells. Cell Tissue Kinet 17: 79-89.
28. Wallen CA, Higashikubo R, Dethlefsen LA, (1984) Murine mammary tumour cells in vitro. I. The development of a quiescent state. Cell Tissue Kinet 17: 65-77.
29. Alves FA, Pires FR, De Almeida OP, Lopes MA, Kowalski LP, (2004) PCNA, Ki-67 and p53 expressions in submandibular salivary gland tumours. Int J Oral Maxillofac Surg 33: 593-597.
30. van Waarde A, Buursma AR, Hospers GA, Kawamura K, Kobayashi T, et al. (2004) Tumor imaging with 2 sigma-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: a feasibility study. J Nucl Med 45: 1939-1945.
31. Endo K, Oriuchi N, Higuchi T, Iida Y, Hanaoka H, et al. (2006) PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol 11: 286-296.
32. Miele E, Spinelli GP, Tomao F, Zullo A, De Marinis F, et al. (2008) Positron Emission Tomography (PET) radiotracers in oncology-utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC). J Exp Clin Cancer Res 27: 52.
33. Rosen EL, Eubank WB, Mankoff DA, (2007) FDG PET, PET/CT, and breast cancer imaging. Radiographics 27Suppl 1: S215-229.
34. Sun H, Mangner TJ, Collins JM, Muzik O, Douglas K, et al. (2005) Imaging DNA synthesis in vivo with 18F-FMAU and PET. J Nucl Med 46: 292-296.
35. Haberkorn U, Ziegler SI, Oberdorfer F, Trojan H, Haag D, et al. (1994) FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol 21: 827-834.
36. Christov K, Grubbs CJ, Shilkaitis A, Juliana MM, Lubet RA, (2007) Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model. Clin Cancer Res 13: 5488-5496.
37. Christov K, Shilkaitis A, Green A, Mehta RG, Grubbs C, et al. (2000) Cellular responses of mammary carcinomas to aromatase inhibitors: effects of vorozole. Breast Cancer Res Treat 60: 117-128.
38. Lubet RA, Steele VE, DeCoster R, Bowden C, You M, et al. (1998) Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model. Carcinogenesis 19: 1345-1351.
39. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, et al. (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99: 167-170.